Fresenius Medical Care wins CIO 100 Award for novel tool to predict intradialytic hypotension

Fresenius Medical Care wins CIO 100 Award for novel tool to predict intradialytic hypotension

Press Release

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has won the prestigious CIO 100 Award. The Company was recognized for its groundbreaking efforts to develop a tool to predict intradialytic hypotension (IDH) before it occurs in hemodialysis patients. IDH is a frequent complication of long-term hemodialysis that can lead to serious clinical outcomes including death and is difficult to predict.

The Renal Research Institute (RRI), a division of Fresenius Medical Care, and the Company's Digital Technology & Innovation (DTI) team, developed a secure data pipeline that collects real time data from dialysis machines and medical sensors throughout the United States at a high frequency.

The increased data flow allows machine learning and cloud computing to develop a real-time IDH prediction for patients. Clinic teams use the information to specially tailor treatment plans and proactively intervene at the point of care preventing IDH, potentially improving patients' morbidity and mortality.

"This is a true example of partnership, collaboration, and teamwork, and we are proud that our commitment to bring it to the next level of these exciting technologies will result in a better care experience for our patients, and most importantly, improve quality of life and patient outcomes," said Franklin W. Maddux, MD, Global Chief Medical Officer and Member of the Board of Fresenius Medical Care.

The CIO 100 Awards celebrates 100 organizations and the teams within them that are using IT in innovative ways to deliver business value, whether by creating competitive advantage, optimizing business processes, enabling growth, or improving relationships with customers. Because it is given to companies and not individuals, it is an acknowledged mark of enterprise excellence.

The Renal Research Institute (RRI) is dedicated to measurably improving outcomes in patients suffering from chronic kidney disease (CKD) through research, technical innovation, implementation of processes and education. RRI strives to achieve its goals through collaboration with national and international academic partners, industry, and not-for-profit organizations operating in the field of kidney disease. RRI fosters its relationship with academic centers of the highest caliber through partnerships. RRI promotes research and education programs with an emphasis on international clinical fellows, scientists, and renal nurses. Through partnerships, RRI is able to enhance the spectrum of comprehensive renal services by advancing peritoneal and hemodialysis therapies through clinical research and the application of practice guidelines and new technology. For more information, visit the Renal Research Institute's website at www.renalresearch.com.

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,116 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

Disclaimer:

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

[Link]

[Link]